Abstract
Anemia is a very frequent clinical finding in elderly people. There are several factors contributing to this condition, namely nutritional deficiencies, inflammation and chronic renal insufficiency. The etiology of chronic kidney disease related anemia is multifactorial, but a relative decrease of erythropoietin production is a major cause. Accordingly, the use of erythropoietic stimulating agents (ESA) is the cornerstone of the therapy in pre-dialysis elderly patients. Resistance or hyporesponsiveness to the treatment happens when the ESA dose needed to produce an otherwise expected increase in hemoglobin is particularly high. Iron deficiency is the commonest cause of resistance to ESA. Inflammation, malnutrition, hyperparathyroidism, drugs and vitamin B12 and folate deficiencies are other important causes of ESA resistance. The clinical investigation of ESA hyporesponsiveness is mandatory, since the correction of chronic kidney disease related anemia is cost saving and decreases the morbidity and mortality in the long term.
Keywords: Erythropoietin, pre-dialysis, elderly, anemia, kidney disease, inflammation.
Related Journals
Current Drug Safety
Inflammation & Allergy - Drug Targets (Discontinued)
Recent Patents on Anti-Infective Drug Discovery
Current Drug Discovery Technologies
Current Drug Targets - Inflammation & Allergy
Current Bioactive Compounds
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Anti-Cancer Agents in Medicinal Chemistry
Current Drug Targets
Letters in Drug Design & Discovery
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Angiogenesis & Therapeutic Targets In Cancer
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development